ReviewMolecular and cellular pediatrics2023
Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE).
Review in Molecular and cellular pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Effects of dual-task exercises on cognitive status, disease activity and quality of life in childhood-onset systemic lupus erythematosus.Lupus science & medicine · 2025Trial
- Assessment of the prevalence of neurological involvement in a pediatric cohort of children with lupus nephritis: retrospective multicenter study.Pediatric nephrology (Berlin, Germany) · 2026Article
- Clinical Features and Outcome of Neuropsychiatric Manifestations in Juvenile Onset Systemic Lupus Erythematosus: Correspondence.Indian journal of pediatrics · 2026Article
- Adverse childhood experiences are associated with disease and mental health outcomes in childhood-onset SLE.Lupus science & medicine · 2026Article
- Unmasking Juvenile Systemic Lupus Erythematosus (JSLE): Multisystemic Manifestations in an Adolescent Male, A Rare Case Report.Clinical case reports · 2026Article
- Suspected levetiracetam drug-induced lupus in a child: A case report.SAGE open medical case reports · 2026Article
- Polygenic Scores and Environmental Factors in Psychiatric Disorders: Gene-Environment Interaction Analyses Using the iPSYCH Study.Research square · 2025Article
- Biomarkers in Pediatric Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review.Life (Basel, Switzerland) · 2025Review
- Headaches in juvenile systemic lupus erythematosus patients: a cross-sectional study.Arquivos de neuro-psiquiatria · 2025Article
- Article
- Age-stratified risk factors and predictive models for progression to lupus nephritis in patients with systemic lupus erythematosus: a review.Frontiers in immunology · 2025Review
- Diagnosis and Management of Pediatric Neuropsychiatric Systemic Lupus Erythematosus: An Update.Paediatric drugs · 2024Review
- Immune-mediated inflammatory diseases (IMIDs) in children: key research questions and some answers.Molecular and cellular pediatrics · 2024Article
- Aseptic Meningitis and White Matter Disease in Childhood-Onset Neuropsychiatric Lupus.Case reports in rheumatology · 2024Article
- Magnetic resonance imaging of the musculoskeletal system in the diagnosis of rheumatic diseases in the pediatric population.Reumatologia · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a rare autoimmune/inflammatory disease with significant morbidity and mortality. Approximately 15-20% of SLE patients develop the disease during childhood or adolescence (juvenile-onset SLE/jSLE). Patients with jSLE exhibit more variable and severe disease when compared to patients with disease-onset during adulthood. Neuropsychiatric (NP) involvement is a clinically heterogenous and potentially severe complication. Published reports on the incidence and prevalence of NP-jSLE are scarce, and the exact pathophysiology is poorly understood.This manuscript provides a review of the existing literature, suggesting NP involvement in 13.5-51% of jSLE patients. Among patients with NP-jSLE affecting the CNS, we propose two main subgroups: (i) a chronic progressive, predominantly type 1 interferon-driven form that poorly responds to currently used treatments, and (ii) an acutely aggressive form that usually presents early during the disease that may be primarily mediated by auto-reactive effector lymphocytes. While this hypothesis requires to be tested in large collaborative international cohort studies, it may offer future patient stratification and individualised care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.